Table 1. Patient characteristics.
| Age/Gender | Disease subtype | Disease duration (years) | Auto-Antibody | Immuno-supessive treament |
| 77/f | Limited | 12 | ANA | - |
| 68/f | Limited | 1 | ACA | AZA |
| 60/f | Diffuse | 2 | ANA | - |
| 57/f | Limited | 7 | ACA | - |
| 60/f | Limited | 2 | ANA | - |
| 64/f | Diffuse | 11 | nd | nd |
| 62/f | Limited | 11 | nd | - |
| 45/f | Limited | 11 | ACA | - |
| 63/m | Diffuse | 5 | - | Cyc, MMF |
| 72/f | Limited | 17 | ACA | - |
| 38/f | Diffuse | 2 | - | Cyc, MMF |
| 83/f | Limited | 11 | - | Penicillamine |
| 50/f | Limited | 7 | - | MTX |
| 60/f | Diffuse | 20 | Scl-70 | Cyc |
Abbreviations: f:female, m:male, ANA: anti-nuclear antibodies; ACA: anti-centromere antibodies; nd: no data, AZA, azathioprine, Cyc: cyclophosphamide, MMF: mycophenolate mofetil, MTX: methotrexate.